ClinicalTrials.gg
CompletedNCT00939588Updated Nov 18, 2016

Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients

A Phase 2 interventional study of Aliskiren/ Valsartan and Telmisartan/ Ramipril in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies testing aliskiren in Hypertension — none open to participants now, none under way, none of them phase 3. aliskiren · Hypertension.

Enrollment
56th of 89
88 · median 253
Started
2009
with 12 others
Phase 2
8 of 89
none open now
Registered
59th of 89
by date
Lead sponsor
12 of 89
Novartis Pharmaceuticals

Among the 89 studies testing aliskiren in Hypertension, this one is the 56th largest by enrollment, is one of 13 that started in 2009, is one of 8 in phase 2, and was the 59th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 89 studies testing aliskiren in Hypertension is open now. The open studies under Hypertension, anywhere →

About aliskiren

aliskiren: first FDA approval 2007 (TEKTURNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 89 studies testing aliskiren in Hypertension as a file.
02

Study summary

This study is designed as a mechanistic study to compare the effect of two different combinations of anti-hypertensive treatments (aliskiren and valsartan vs. telmisartan and ramipril) on the renin-angiotensin-aldosterone system (RAAS) in patients with moderate hypertension.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Aliskiren,
  • hypertension,
  • renin-angiotensin-aldosterone system
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females of non-, 18 to 65 years of age with moderate hypertension
  • Patients who are eligible and able to participate in the study

Exclusion criteria

Exclusion criteria:

  • Severe hypertension or secondary form of hypertension.
  • Serum potassium > 5.1 mEq/L (mmol/L)
  • Heart failure
  • Any history of hypertensive encephalopathy or cerebrovascular accident; any history of , myocardial infarction, coronary bypass surgery or percutaneous coronary intervention
  • Uncontrolled or life-threatening arrythmia

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Aliskiren and Valsartan

    Drug: Aliskiren/ Valsartan

  • Active comparator
    Telmisartan and Ramipril

    Drug: Telmisartan/ Ramipril

Interventions

06

What researchers measure

Primary outcomes

  1. Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on 24-hour urinary aldosterone

    Time frame: 56 days

Secondary outcomes

  1. Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on Plasma Renin Activity (PRA)and angiotensin II

    Time frame: 56 days

  2. Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on mean sitting systolic and diastolic blood pressure

    Time frame: 56 days

  3. Assess safety and tolerability of aliskiren + valsartan and ramipril + telmisartan

    Time frame: 56 days

07

Study locations

1 site
  • Novartis Investigative Site
    Moscow, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009 and a primary completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2009
First posted
Jul 15, 2009
Start
Jul 2009
Primary completionActual
Dec 2009
Last update
Nov 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00939588
First posted
Jul 15, 2009
Start date
Jul 2009
Primary completion
Dec 2009
Last update
Nov 18, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aliskiren · Valsartan

Start the discussion